New HIV treatment vaccines successfully tested on people

Finding a vaccine for HIV is one of the most important issues in the fight against AIDS in the world.

People often say "if you want to cut diamonds, you have to use diamonds ", so why not " take the virus to kill the virus "? It is also the idea of ​​a group of scientists from Brigham and Women Hospital (UK) and Harvard Medical School to study a vaccine to prevent HIV virus . Specifically, scientists used a common flu-inducing virus to prepare it into a desired vaccine.

They then conducted small-scale clinical trials on a number of volunteers who participated and initial results were encouraging when the vaccine prepared from a mixture of flu viruses and HIV was confirmed to be safe. and help the body produce effective immune responses in the face of HIV infection. However, the scientists claim that the study is not necessarily successful in creating a complete vaccine for the deadly HIV virus, which only helps the research team take a step forward on the way to conquer the type. This extremely dangerous virus.

Previously, scientists have done a lot of research to prepare a special vaccine for HIV with many different approaches but as a result, they still " empty their hands ". One of the approaches is to select a certain amount of HIV that the human immune system can resist and bring it into the body thanks to a drug cover. Later, the scientists found a way to accelerate this method by adding another non-dangerous vector virus to increase the body's immunity on a large scale.

However, this method also has drawbacks because if the human body had ever encountered a vector virus , it would have the opposite effect when the system warned early and attacked them, which broke. The process of vaccine activity because the protection of the immune system will only stop at the virus vector level rather than the HIV virus. Since then, the uncompromising goal of this method is to find a virus that is not dangerous but rare. That's why this new study attracts a lot of scientific attention - especially those working in the health sector.

The research team chose two strains of the common cold flu virus, but the human body has very little chance to confront at least once with them. They then attach them to membrane molecules that cover the surface of the HIV virus. This is the key factor for HIV to enter the cell so attaching a weak vector virus to this position will direct the immune system to focus on destroying the vector virus and puncture the membrane to attack it. HIV positive right from the inside.

Scientists have tested the two types of viruses on 217 healthy volunteers in the United States, East Africa and South Africa. Each person was given at least one dose of this new vaccine and the research team closely monitored the physiological manifestations of the person injected after that in 2 periods of 3 months and 6 months. As a result, the volunteers' bodies absorbed the vaccine quite well and did not produce side effects, the amount of antibodies increased after the vaccine was introduced into the body - a signal that the immune system worked better when given. head with HIV.

Finding a vaccine for HIV is one of the most important issues in the fight against AIDS in the world. Since 1981, about 78 million people have been infected with HIV, the virus that destroys immune cells and makes the body more susceptible to infections, pneumonia and other opportunistic diseases. About 39 million of them died, according to UN statistics.

Antiretroviral drugs (ARVs) invented in the mid-1990s can treat infections, but cannot cure AIDS or prevent infection with HIV. The treatment of HIV infection now lasts a lifetime and contains many unwanted side effects. For many health systems around the globe, the cost of buying ARVs for people is increasing and becomes a major burden on the national budget.